Haleon plc (HLN) research

Haleon plc
ShareXLinkedInReddit
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Last price
$9.25
As of

Haleon plc (HLN): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-18.

As of . Source: SEC EDGAR filings for HLN. Method and limitations.

SHARE THIS CARD

Share the HLN intelligence card

A branded snapshot of HLN: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion HLN intelligence card preview
Post to X
LIVE TERMINAL

See HLN live in the terminal

Track HLN's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live HLN terminal, free

Active signals for HLN

FREE, NO ACCOUNT

Every signal on HLN, as it fires

You are seeing 5 of 24 signals recorded on HLN since 2026-05-29.

The five above landed across 2 days. The other 19 were recorded on 4 other days. 16 of the 24 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in HLN (2026Q2)

Manager / securityMarket value% portfolioQoQ
Point72 Asset Management, L.P.CUSIP 405552100 · 2026Q2$86.4M0.10%,
D. E. Shaw & Co., Inc.CUSIP 405552100 · 2026Q2$23.6M0.01%,
CITADEL ADVISORS LLCCUSIP 405552100 · 2026Q2$15.5M0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP 405552100 · 2026Q2$8.7M0.00%,
Bridgewater Associates, LPCUSIP 405552100 · 2026Q2$3.8M0.02%,
TWO SIGMA INVESTMENTS, LPCUSIP 405552100 · 2026Q2$780K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, HLN

HLN against its peers

HLN's operating margin of 21.9% ranks in the 91st percentile of 16 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-05-31.

MetricHLNPeer medianPercentilen
Revenue FY11.0B GBPn/an/a0
Revenue YoY-1.8%-4.3%585
Gross margin64.2%49.8%7513
Operating margin21.9%0.8%9116
Net margin15.2%-4.9%8117
Return on equity10.2%-5.5%8314

Peers (18): ELAN, KNSA, INDV, RGC, CURLF, HCM, PBH, ALVO, PRGO, ETON, GTBIF, HROW, CRON, TLRY, VREOF, AQST, EOLS, KMDA. Left out: GALDY (no annual filing), TAK (period gap), JHPCY (no annual filing), SGIOF (no annual filing), RDY (period gap), HYPMY (no annual filing), EVO (period gap). Fiscal periods ending between 2025-06-30 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (HLN: 20-F), reported in GBP. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more HLN signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to HLNand get the insider, 13F, options, and confluence read in one view.

Open the live HLN terminal, free